Comprehensive Guide to the NCT02937233 Protocol: CRISPR-Cas9 Gene Editing in T-Cell Therapy

To access and understand the NCT02937233 protocol, researchers should consult the official ClinicalTrials.gov record and the supplementary materials of the primary publication in the journal Science (Stadtmauer et al., 2020). This landmark Phase I trial utilized CRISPR-Cas9 to edit three genes in human T cells to treat refractory cancer, establishing the foundational safety and feasibility for multiplexed genome editing in clinical oncology.

Understanding the Significance of NCT02937233

The clinical trial identified by the identifier NCT02937233 represents a pivotal moment in the history of genomic medicine. Officially titled "Phase I Study of NY-ESO-1-redirected CRISPR (Edited T Cells) in Patients With Advanced Cancer," it was the first study in the United States to test the safety and feasibility of CRISPR-Cas9 technology for multiplexed gene editing in humans.

As we evaluate this protocol in 2026, its legacy is evident in the current landscape of immunotherapy. The study was sponsored by the University of Pennsylvania in collaboration with the Parker Institute for Cancer Immunotherapy and TMUNITY Therapeutics. The primary objective was not merely to treat a specific cancer, but to prove that the complex machinery of CRISPR could be applied to human cells, expanded in a laboratory setting, and re-infused into patients without inducing immediate, catastrophic toxicity or "off-target" genetic damage.

The protocol focuses on patients with NY-ESO-1 positive tumors, specifically those with multiple myeloma, melanoma, or synovial sarcoma that had failed standard treatments. By targeting the NY-ESO-1 antigen, which is frequently expressed in various cancers but rarely in healthy adult tissues, the researchers aimed to direct the immune system's T cells to kill malignant cells with high precision.

How to Access the NCT02937233 Protocol PDF

For those seeking the full "NCT02937233 protocol pdf," it is important to distinguish between the clinical summary found on public registries and the full clinical study protocol (CSP) used by investigators.

Official ClinicalTrials.gov Record

The most immediate source of information is the ClinicalTrials.gov database. While the site provides a comprehensive summary of the study design, eligibility, and primary outcomes, the full technical protocol is often uploaded as an attachment only after the trial has reached a specific stage of reporting. To find it:

1. Navigate to the ClinicalTrials.gov homepage.
2. Search for the unique identifier: NCT02937233.
3. Check the "Study Record Detail" and look for a section titled "Study Documents." If the investigators have made the PDF public, it will be listed here with a version date.

Academic and Journal Supplements

The most detailed version of the NCT02937233 protocol is typically found as a supplement to the primary results paper. In February 2020, the investigative team published their findings in Science under the title "CRISPR-edited T cells in patients with refractory cancer."

• Science Magazine (AAAS): The supplementary materials for this article contain dozens of pages detailing the manufacturing process, the specific CRISPR guide RNA (gRNA) sequences, and the bioinformatics pipeline used to monitor for off-target effects.
• DOI Access: Utilizing a DOI (Digital Object Identifier) resolver like CrossRef or PubMed (PMID: 32029687) will lead directly to the publication and its associated protocol documents.

Institutional Repositories

The University of Pennsylvania's Abramson Cancer Center or the Parker Institute may host technical briefs or white papers derived from the original protocol for use by other research institutions. These documents provide the "Why" and "How" behind the specific choices of gene knockouts.

Technical Specifications of the Intervention

The NCT02937233 protocol is distinguished by its use of "multiplex" editing. Rather than changing a single gene, the protocol required the simultaneous modification of four different genetic loci. This complexity is why the protocol remains a core reference for cell therapy developers today.

The Four Genetic Modifications

The protocol outlined a specific strategy to enhance the T cells' ability to survive and fight tumors:

1. Synthetic TCR Insertion: A lentiviral vector was used to introduce a T-cell receptor (TCR) that recognizes the NY-ESO-1 antigen presented by HLA-A*02:01.
2. TRAC Knockout: CRISPR was used to delete the endogenous T-cell receptor alpha chain (TRAC). This prevents the cell's original receptor from competing with the new synthetic one.
3. TRBC Knockout: Similar to TRAC, the T-cell receptor beta chain (TRBC) was deleted to ensure the purity of the engineered receptor and reduce the risk of graft-versus-host-like interactions.
4. PDCD1 (PD-1) Knockout: The gene encoding the PD-1 protein, a known "checkpoint" that tumors use to turn off T cells, was deleted. By removing PD-1, the protocol aimed to make the T cells more resistant to the immunosuppressive environment of the tumor.

Manufacturing and Expansion

The protocol details a rigorous manufacturing timeline. T cells were harvested from the patient via leukapheresis, edited in a clean-room environment using electroporation to introduce the Cas9 protein and gRNAs, and then expanded using cytokines like IL-2. The final product was then tested for sterility, purity, and "editing efficiency"—the percentage of cells that actually contained all intended modifications.

Patient Eligibility and Enrollment Criteria

The NCT02937233 protocol was highly restrictive, reflecting its Phase I status and the need for patient safety. To be considered for enrollment, patients had to meet several physiological and genetic "gates."

Inclusion Criteria

• Antigen Expression: The patient’s tumor had to be laboratory-confirmed as NY-ESO-1 positive (at least 1+ staining in 25% of cells via immunohistochemistry).
• HLA Type: Because the specific TCR used in the study recognizes NY-ESO-1 in the context of the HLA-A02:01 molecule, patients had to be HLA-A02:01 positive.
• Diagnosis: The study accepted patients with multiple myeloma (relapsed or refractory), melanoma (Stage III or IV), or synovial sarcoma that was metastatic or unresectable.
• Organ Function: Patients required robust bone marrow, kidney, and liver function to withstand the lymphodepleting chemotherapy (usually cyclophosphamide and fludarabine) administered before the T-cell infusion.

Exclusion Criteria

• Prior Therapy: Patients could not have received certain types of immunotherapy or gene therapy within a specific window before the study.
• Active Infections: Specifically, patients with HIV, Hepatitis B, or Hepatitis C were excluded due to the risk of viral reactivation during the immunosuppressive phase of the trial.
• CNS Involvement: Active brain metastases were generally an exclusion factor because of the risk of neurotoxicity associated with T-cell therapies.

Detailed Comparison of Engineering Strategies

The NCT02937233 protocol was unique compared to earlier CAR-T or TCR-T trials. The following table highlights the technical differences between the CRISPR-edited approach and traditional T-cell engineering.

Monitoring and Safety Endpoints

The primary goal of the NCT02937233 protocol was to establish safety. In Phase I clinical trials, "Safety and Feasibility" are the paramount metrics.

Primary Endpoints

• Dose-Limiting Toxicities (DLTs): Monitoring for severe adverse events within the first 28 days post-infusion. This includes Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).
• Feasibility of Manufacturing: Determining if the team could successfully produce the edited cells within the required timeframe for a critically ill patient.

Secondary and Exploratory Endpoints

• Cell Persistence: How long the CRISPR-edited cells survived in the patient's blood. The study used quantitative PCR (qPCR) to track the "mark" left by the edits.
• Anti-Tumor Activity: While not the main goal, the researchers monitored tumor shrinkage using RECIST 1.1 criteria or IMWG criteria for myeloma.
• Off-Target Analysis: Using advanced sequencing (like GUIDE-seq or whole-genome sequencing), the protocol required checking for unintended edits in the DNA that might lead to secondary cancers.

Operational Limitations and Challenges

The execution of the NCT02937233 protocol was not without significant hurdles. For researchers analyzing the PDF today, understanding these limitations is essential for contextualizing the results.

1. Editing Efficiency vs. Expansion: One major challenge was ensuring that the cells that were successfully edited (three knockouts + one insertion) could also grow well enough to form a therapeutic dose. In some cases, the double-strand breaks caused by CRISPR can trigger a p53-mediated DNA damage response that slows cell growth.
2. Chromosomal Translocations: Because the protocol targeted three different genes simultaneously, there was a theoretical risk that the "cut" ends of different chromosomes could fuse together (e.g., a translocation between Chromosome 1 and Chromosome 14). The protocol included specific assays to detect these rare events.
3. Immunogenicity of Cas9: Since Cas9 is derived from bacteria (S. pyogenes), there was a concern that the patient's immune system might recognize and destroy the edited cells. The protocol monitored for anti-Cas9 antibodies and T-cell responses.

Regulatory and Ethical Oversight

Given the "first-in-human" nature of this CRISPR protocol, the oversight was exceptionally rigorous. The protocol had to pass through several layers of review:

• Institutional Review Board (IRB): Local ethics committee at the University of Pennsylvania.
• The Recombinant DNA Advisory Committee (RAC): A national committee at the NIH that reviewed the safety of gene transfer protocols (at the time of the trial's inception).
• FDA Office of Tissues and Advanced Therapies (OTAT): The federal body that granted the Investigational New Drug (IND) status.

The protocol includes detailed "Stopping Rules," which are predefined conditions under which the trial would be immediately halted if a patient suffered a specific type of severe side effect.

Practical Expert Guidance for Researchers

If you are using the NCT02937233 protocol as a template for new research in 2026, consider the following technical nuances:

• Guide RNA Selection: The gRNAs used in this protocol were chemically modified to increase stability and reduce the innate immune response within the T cell. This is now a standard practice, but the NCT02937233 protocol was among the first to validate it clinically.
• The Shift to Base Editing: While NCT02937233 used traditional Cas9 (which creates double-strand breaks), newer protocols often favor "base editing" or "prime editing" to avoid the risk of translocations and p53 activation.
• Persistence Data: Long-term follow-up from this study showed that the edited cells could persist for up to 9 months, which was significantly longer than previous TCR-T therapies that did not use gene editing to remove the endogenous receptor.

Frequently Asked Questions

What was the outcome of the NCT02937233 trial?

The trial successfully demonstrated that CRISPR-edited T cells are safe and feasible for human infusion. The cells were well-tolerated, and while the anti-tumor responses were modest (typical for a Phase I safety study), the persistence of the cells provided a "proof-of-concept" that multiplexed editing does not inherently kill the T cell's ability to survive in the body.

Why did the protocol target TRAC and TRBC?

By knocking out the T-cell receptor alpha (TRAC) and beta (TRBC) chains, the researchers ensured that the only TCR expressed on the surface of the cell was the synthetic one targeting NY-ESO-1. This prevents "TCR mispairing," where a synthetic chain pairs with a natural chain, potentially creating a new, "autoreactive" receptor that could attack the patient's healthy tissue.

Is the NCT02937233 protocol still active in 2026?

As of 2026, the primary study is completed, and the results have been fully analyzed and published. However, the protocol serves as the "ancestor" for many ongoing Phase II and Phase III trials that use more advanced editing tools (like CRISPR-Cas12a or base editors) and target different antigens like CD19 or BCMA.

How many genes were edited in the NCT02937233 protocol?

The protocol involved editing four distinct genetic elements: knocking out three genes (TRAC, TRBC, and PDCD1) and knocking in one gene (the NY-ESO-1 TCR). This made it the most complex clinical gene-editing protocol of its time.

What were the most common side effects reported?

The most common side effects were related to the lymphodepleting chemotherapy, such as fatigue, nausea, and low blood cell counts (anemia and neutropenia). No severe Cytokine Release Syndrome or neurotoxicity directly attributed to the CRISPR edits was observed in the initial cohort.

Can I use this protocol for a different type of cancer?

The general framework of the NCT02937233 protocol—leukapheresis, CRISPR editing, expansion, and re-infusion—is highly adaptable. However, a new protocol would require a different TCR or CAR sequence and potentially different gRNAs depending on the specific tumor biology of the new target cancer.

Next Actions for Clinical Researchers

For those looking to build upon this work, the next logical step is to review the Primary Analysis Publication (Stadtmauer et al., Science, 2020) and the Long-term Follow-up data which has been presented at ASCO and ASH meetings between 2022 and 2025. These documents provide the longitudinal data on cell persistence and genomic stability that are not present in the original 2016 protocol PDF.

If you are developing a new IND (Investigational New Drug) application, pay particular attention to the "Quality Control" sections of the NCT02937233 protocol. The FDA's expectations for off-target analysis and translocation monitoring have evolved since this trial began, and the methods used in NCT02937233 represent the baseline "gold standard" from which modern requirements have grown.